breast cancer
Oncology · 2006–2024
13decisions
10medicines
2carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| zoledronic acid Adjuvant management of breast cancer in post-menopausal women. Treatment duration of up to 3 years at a dose of 4 mg IV every six months. | Jul 2023 | Recommended with restriction | no section in document |
| goserelin Preservation of fertility in premenopausal women with breast cancer undergoing chemotherapy to reduce chemotherapy-induced menopause. | Nov 2016 | Deferred | input received Breast Cancer Network Australia |
| netupitant and palonosetron Prevention of nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy (HEC) and anthracycline plus cyclophosphamide… | Nov 2015 | Recommended with restriction | none received |
| anastrozole, everolimus, exemestane, goserelin, letrozole Breast cancer in male and female patients. The submission sought to amend PBS restrictions to allow males with breast cancer equitable access to these five… | Nov 2014 | Recommended | no section in document |
| eribulin mesilate Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease,… | Mar 2013 | Not recommended | unclear |
| eribulin mesilate Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease,… | Nov 2013 | Recommended with restriction | unclear |
| docetaxel Adjuvant treatment of operable breast cancer in combination with cyclophosphamide. | Nov 2009 | Recommended with restriction | no section in document |
| paclitaxel, nanoparticle albumin-bound Metastatic breast cancer after failure of prior therapy which includes an anthracycline. | Dec 2008 | Not recommended | no section in document |
| aprepitant Management of nausea and vomiting associated with cytotoxic chemotherapy, being used to treat breast cancer, in combination with a 5HT3 antagonist and… | Mar 2006 | Recommended with restriction | no section in document |
| aprepitant Management of nausea and vomiting associated with cytotoxic chemotherapy in patients undergoing treatment for breast cancer with cyclophosphamide and an… | Mar 2006 | Recommended with restriction | no section in document |
| Pegfilgrastim prophylaxis of chemotherapy induced neutropenia in patients with breast cancer who are undergoing adjuvant chemotherapy with a docetaxel containing regimen | Nov 2006 | Recommended | no section in document |
| pegfilgrastim Primary prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer undergoing adjuvant chemotherapy with docetaxel in combination with an… | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
Breast Cancer Network Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.